Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study

Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., Poulter, N., Lip, G. Y.H., Patel, A., on behalf of the ADVANCE Collaborative Group · 2009 · European Heart Journal

Abstract

AIMS: The aim of this study was to investigate serious clinical outcomes associated with atrial fibrillation (AF) and the effects of routine blood pressure lowering on such outcomes in the presence or absence of AF, among individuals with type 2 diabetes. METHODS AND RESULTS: About 11 140 patients with type 2 diabetes (7.6% of whom had AF at baseline) were randomized to a fixed combination of perindopril and indapamide or placebo in the Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. We compared total mortality and cardiovascular disease outcomes and effects of randomized treatment for 4.3 years on such outcomes between patients with and without AF at baseline. After multiple adjustments, AF was associated with a 61% (95% confidence interval 31-96, P < 0.0001) greater risk of all-cause mortality and comparable higher risks of cardiovascular death, stroke, and heart failure (all P < 0.001). Routine treatment with a fixed combination of perindopril and indapamide produced similar relative, but greater absolute, risk reductions for all-cause and cardiovascular mortalities in patients with AF, compared with those without AF. The number of patients needed to be treated with perindopril-indapamide for 5 years to prevent one cardiovascular death was 42 for patients with AF and 120 for patients without AF at baseline. CONCLUSION: Atrial fibrillation is relatively common in type 2 diabetes and is associated with substantially increased risks of death and cardiovascular events in patients with type 2 diabetes. This arrhythmia identifies individuals who are likely to obtain greater absolute benefits from blood pressure-lowering treatment. Atrial fibrillation in diabetic patients should be regarded as a marker of particularly adverse outcome and prompt aggressive management of all risk factors.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehp055

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. 2004, Diabetes Care, 21, 1047

Cited by

See all 246

Metadata

Authors
Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., Poulter, N., Lip, G. Y. H., Patel, A., & on behalf of the ADVANCE Collaborative Group
Affiliations
  • The University of Sydney (AU)
  • Baker Heart and Diabetes Institute (AU)
  • The University of Melbourne (AU)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Imperial College London (GB)
  • Birmingham City Hospital (GB)
Corresponding author
Patel, A.
Venue
European Heart Journal
Published
2009-03-11
Volume
30
Issue
9
Pages
1128-1135
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2128136679
Cited by
239
References
27
Citations by year
2026: 8 · 2025: 9 · 2024: 12 · 2023: 12 · 2022: 19 · 2021: 25 · 2020: 17 · 2019: 16 · 2018: 17 · 2017: 12 · 2016: 17 · 2015: 18 · 2014: 12 · 2013: 12 · 2012: 10
FWCI
7.15
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • ResearchSpace (University of Auckland) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
atrial fibrillation, type 2 diabetes, blood pressure reduction, perindopril, indapamide, ADVANCE trial, cardiovascular mortality, stroke, heart failure, all-cause mortality, cardiovascular risk, antihypertensive therapy
MeSH terms
Aged, Antihypertensive Agents, Atrial Fibrillation, Blood Glucose, Diabetic Angiopathies, Drug Therapy, Combination, Female, Humans, Hypertension, Indapamide, Male, Middle Aged, Risk Factors, Confidence Intervals, Treatment Outcome, Perindopril

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. https://app.cochat.ai/papers/10.1093/eurheartj/ehp055
The paper
Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., Poulter, N., Lip, G. Y. H., Patel, A., & on behalf of the ADVANCE Collaborative Group. (2009). Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehp055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.